Clinical Trial Update: High Dose IL 2 and Entinostat in RCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating high-dose IL-2 and entinostat in Renal Cell Carcinoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Entinostat (entinostat)
• high-dose IL-2 (interleukin-2)

Snippet

Sponsor: Roberto Pili | Conditions: Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING